Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

13.60
+0.81506.38%
Post-market: 13.52-0.0750-0.55%19:51 EDT
Volume:4.12M
Turnover:54.96M
Market Cap:1.41B
PE:-2.61
High:13.71
Open:12.82
Low:12.73
Close:12.78
Loading ...

Intellia Therapeutics Reports Positive Phase 1 Trial Results

TIPRANKS
·
19 May

Intellia Therapeutics: Promising Early Data on Nex-Z Met with Caution Due to Small Sample Size and Need for Further Trials

TIPRANKS
·
19 May

Intellia Therapeutics Says Drug Shows Potential in Phase 1 Transthyretin Amyloidosis Trial

MT Newswires Live
·
19 May

Intellia Therapeutics announces two-year follow-up data from trial of nex-z

TIPRANKS
·
18 May

Truist Financial Keeps Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
13 May

Stock Track | Intellia Therapeutics Soars 7.70% Pre-Market Following Evercore ISI's Buy Rating Reiteration

Stock Track
·
12 May

Stock Track | Intellia Therapeutics Soars 7.70% in Pre-Market Following Evercore ISI's Buy Rating Reiteration

Stock Track
·
12 May

Intellia Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
12 May

Evercore ISI Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
12 May

Stock Track | Intellia Therapeutics Soars 5.07% Pre-Market on Positive Analyst Ratings

Stock Track
·
09 May

RBC Trims Price Target on Intellia Therapeutics to $30 From $32, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 May

Intellia Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
09 May

Intellia Therapeutics price target lowered to $10 from $14 at Citi

TIPRANKS
·
09 May

Bank of America Securities Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
09 May

Intellia Therapeutics: Hold Rating Amid Regulatory Challenges and Strategic Consolidation

TIPRANKS
·
09 May

Intellia Therapeutics: Promising CRISPR-Based Therapies Drive Buy Rating Amid Clinical Advancements

TIPRANKS
·
09 May

BUZZ-U.S. STOCKS ON THE MOVE-Tapestry, Carvana, PPG Industries

Reuters
·
08 May

BUZZ-Intellia Therapeutics rises on narrower Q1 loss

Reuters
·
08 May

Stock Track | Intellia Therapeutics Soars 10.84% on Strong Q1 Results and Extended Cash Runway

Stock Track
·
08 May

Intellia Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May